BBIO

BridgeBio Pharma, Inc.

27.92 USD
-0.03 (-0.09%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

BridgeBio Pharma, Inc. stock is up 9.6% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 May 17:24 16 Aug, 2024 35.00 CALL 84 3008
16 May 18:11 16 Aug, 2024 35.00 CALL 93 3008
16 May 19:35 17 Jan, 2025 35.00 CALL 66 8813
17 May 19:24 17 Jan, 2025 40.00 CALL 74 1851
17 May 19:26 17 Jan, 2025 40.00 CALL 509 1851
20 May 15:08 17 Jan, 2025 30.00 PUT 325 162
20 May 16:26 16 Aug, 2024 40.00 CALL 300 7040
21 May 15:02 19 Jul, 2024 35.00 CALL 100 358
23 May 16:31 21 Jun, 2024 30.00 CALL 190 1851
24 May 18:41 19 Jul, 2024 30.00 CALL 140 2681

About BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.

  • HC Wainwright & Co.
    Mon May 20, 06:22
    buy
    confirm
  • Evercore Partners
    Tue May 14, 05:16
    buy
    initial